TABLE 4.

Statistical analysis of percent CD4 CD8 DP thymocytes and CD4 SP/CD8 SP thymocyte ratio 6 weeks after infection of thymus/liver grafts with HIV-1 ACH142-8G9, ACH142-32D2, ACH142-^*E11, or NL4-3, or mock infection^a

Between-group comparison	Δ Mean	Δ SE	Lower 95% CL	Upper 95% CL	Probability Δ = 0
% CD4 CD8 DP thymocytes
Mock-8G9	−1.24	4.51	−14.46	11.97	1.000
Mock-32D2	0.36	4.51	−12.86	13.57	1.000
Mock-E11 (CCR5 +/+ grafts)	21.84	3.93	10.33	33.36	<0.001
Mock-E11 (CCR5 +/Δ32)	−7.44	4.97	−21.99	7.10	0.666
Mock–NL4-3	71.42	2.46	64.22	78.62	<0.001
8G9-32D2	1.60	5.86	−15.57	18.77	1.000
8G9-E11 (CCR5 +/+ grafts)	23.09	5.43	7.19	38.98	<0.001
8G9-E11 (CCR5 +/Δ32)	−6.20	6.22	−24.41	12.01	0.918
8G9–NL4-3	72.67	4.48	59.55	85.78	<0.001
32D2-E11 (CCR5 +/+ grafts)	21.49	5.43	5.59	37.38	<0.002
32D2-E11 (CCR5 +/Δ32)	−7.80	6.22	−26.01	10.41	0.809
32D2–NL4-3	71.07	4.48	57.95	84.18	<0.001
E11 (CCR5 +/+ graft)–E11 (CCR5 +/Δ32)	−29.29	5.81	−46.30	−12.27	<0.001
E11 (CCR5 +/+ graft)–NL4-3	49.58	3.89	38.18	60.98	<0.001
E11 (CCR5 +/Δ32)–NL4-3	78.87	4.94	64.41	93.32	<0.001
CD4 SP/CD8 SP thymocyte ratio
Mock-8G9	0.34	0.26	−0.42	1.10	0.780
Mock-32D2	0.34	0.26	−0.42	1.10	0.780
Mock-E11 (CCR5 +/+ grafts)	1.24	0.23	0.58	1.91	<0.001
Mock-E11 (CCR5 +/Δ32)	0.65	0.29	−0.19	1.49	0.219
Mock-NL4-3	2.19	0.20	1.77	2.60	<0.001
8G9-32D2	0.00	0.34	−0.99	0.99	1.000
8G9–E11 (CCR5 +/+ grafts)	0.90	0.31	−0.01	1.82	0.055
8G9–E11 (CCR5 +/Δ32)	0.31	0.36	−0.74	1.36	0.953
8G9–NL4-3	1.85	0.26	1.09	2.60	<0.001
32D2–E11 (CCR5 +/+ grafts)	0.91	0.34	−0.01	1.82	0.055
32D2-E11 (CCR5 +/Δ32)	0.31	0.36	−0.74	1.36	0.953
32D2-NL4-3	1.85	0.26	1.09	2.60	<0.001
E11 (CCR5 +/+ graft)–E11 (CCR5 +/Δ32)	−0.59	0.33	−1.57	0.39	0.490
E11 (CCR5 +/+ graft)–NL4-3	0.95	0.22	0.29	1.60	0.001
E11 (CCR5 +/Δ32)–NL4-3	1.54	0.28	0.71	2.37	<0.001

^aCorresponding summary measures are given in Table 5.